Table 4. Recommendations of adjuvant therapy after neoadjuvant therapy.

Stratification	Level I recommendations	Level II recommendations	Level III recommendations
pCR	−	−	Continue the use of PD-1 inhibitors for a full year in patients who have been treated with PD-1 inhibitors during neoadjuvant therapy (2B)
nonpCR	Capecitabine (1A)	Olaparib (in the presence of a BRCA mutation) (1B)	Continue the use of PD-1 inhibitors for a full year in patients who have been treated with PD-1 inhibitors during neoadjuvant therapy (2B)

PCR, pathological complete response; nonpCR, non-pathological complete response.